Identifying and Classifying Quality of Life Tools for Assessing Neurogenic Bowel Dysfunction After Spinal Cord Injury
Top Spinal Cord Inj Rehabil, 2019 · DOI: 10.1310/sci18-00019 · Published: August 7, 2018
Simple Explanation
This research identifies and classifies tools used to measure the impact of neurogenic bowel dysfunction (NBD) on the quality of life (QoL) for individuals with spinal cord injury (SCI). It categorizes these tools as either objective (societal viewpoint) or subjective (personal viewpoint) based on Dijkers’ theoretical QoL framework. The study found 13 tools that assess the influence of NBD on QoL in SCI patients. The Health Utility Index (HUI-III) was identified as the only tool providing data on “QoL as utility,” while the validated NBD score was the only condition-specific tool assessing QoL as “subjective well-being.” The review emphasizes the importance of selecting appropriate QoL tools to accurately measure individual progress and treatment effects on QoL, which can inform practice and policy related to resource allocation for bowel care post SCI.
Key Findings
- 1Thirteen QoL outcome tools were identified, five objective and eight subjective, used in studies assessing the influence of NBD on QoL in SCI.
- 2The Health Utility Index (HUI-III) was the only identified tool that provided data on “QoL as utility” regarding the impact of NBD.
- 3The NBD score was identified as the only condition-specific tool to assess QoL as “subjective well-being.”
Research Summary
Practical Implications
Informed Practice
Clinicians can use the identified and classified QoL tools to assess the impact of NBD on QoL in patients with SCI, guiding treatment decisions.
Resource Allocation
The objective QoL measures, especially the HUI-III, can inform decision-makers on how to allocate funds and resources for various interventions related to bowel care post-SCI.
Treatment Advancements
Advancing treatments for bowel management after SCI have the potential to improve participation and QoL, and the use of condition-specific validated outcome tools is essential for measuring individual progress and treatment effects.
Study Limitations
- 1Samples with <50% of individuals with SCI were excluded, which may introduce bias in the results.
- 2Further, information on cross-cultural applications were not available.
- 3It is also possible that we did not identify all relevant articles for inclusion.